Robert Plenge MD, Ph.D., Appointed Chief Research Officer of Bristol Myers Squibb, to Board of Directors
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the company has appointed Robert Plenge MD., Ph.D., to the company’s Board of Directors, effective September 10, 2026.
September 14, 2026